BioSpace News Archive

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), today announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential six-month intravitreal treatment targeting wet age-related macular degeneration (wet AMD).

Fate Therapeutics, Inc. (NASDAQ: FATE), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) NK cell product candidate.

Denali Therapeutics Inc. will highlight during a corporate presentation at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, at 11:15 a.m. Eastern Time.

Visby Medical™, a leading medical diagnostic company, today announced that it will make its debut appearance at the 40th Annual J.P. Morgan Healthcare Conference.

BioLife Solutions, Inc., a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, announced preliminary revenue for the fourth quarter and full year 2021.

Peptilogics, a biotech company that engineers peptide therapeutics to radically improve the treatment landscape for patients with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) for PLG0206 to treat periprosthetic joint infection (PJI) allowing the Phase 1b study to proceed.

Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2021, provided product revenue guidance for 2022 and provided an update on its INTERCEPT Blood System for Cryoprecipitation offering, which is used to produce INTERCEPT Fibrinogen Complex.

Aptorum Group Limited announced that its subsidiary company, Aptorum Innovations Holding Limited, has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.

Regulatory News: Aptorum Group Limited announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by Staphylococcus aureus.

Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the appointment of Dr. Nathan Lack and Dr. Marc Horwitz to the Scientific Advisory Board.